September 14, 2021 Rentschler Biopharma featured in the Biotech Issue of Going Public
Germany is an essential manufacturing hub for high-quality biopharmaceuticals. Especially during the pandemic, German biotech companies have demonstrated what can be achieved together as a network.
In the annual biotech issue of Going Public, Dr. Sabine Sydow of vfa bio and Dr. Frank Mathias, CEO Rentschler Biopharma and chairman of vfa bio, address the role of antibodies as an innovation driver and elaborate on their relevance for the German biotechnology sector.
In a second article, Dr. Georg Kääb speaks to Dr. Patrick Meyer, Director Business Development, about production capacities for biotechnological manufacturing processes and how we offer fast, flexible and reliable services to meet our clients’ needs globally.
For more details (German content) please click here.
To learn more about our client offerings, please click here.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication